Nature structural & molecular biology, 2010-02, Vol.17 (2), p.248-250
2010
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Structural basis of respiratory syncytial virus neutralization by motavizumab
- Ist Teil von
- Nature structural & molecular biology, 2010-02, Vol.17 (2), p.248-250
- Ort / Verlag
- United States
- Erscheinungsjahr
- 2010
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Motavizumab is approximately tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1545-9993eISSN: 1545-9985DOI: 10.1038/nsmb.1723Titel-ID: cdi_pubmed_primary_20098425
- Format
- –
- Schlagworte
- Antibodies, Monoclonal - chemistry, Antibodies, Monoclonal - immunology, Antibodies, Monoclonal, Humanized, Antibodies, Neutralizing - chemistry, Antibodies, Neutralizing - immunology, Antibodies, Viral - chemistry, Antibodies, Viral - immunology, Antiviral Agents - chemistry, Antiviral Agents - immunology, Crystallography, X-Ray, Epitopes - chemistry, Epitopes - immunology, Humans, Models, Molecular, Neutralization Tests, Protein Structure, Quaternary, Respiratory Syncytial Viruses - immunology, Viral Fusion Proteins - chemistry, Viral Fusion Proteins - immunology